Get started
Author

Julita Nowicka

Observed name: J. Nowicka
ORCID: 0000-0002-0596-9377
Observed ORCID: 0000-0002-0596-9377
OpenAlex ID: A5069173513
Comparative analysis of RNA 3D structure prediction methods: towards enhanced modeling of RNA–ligand interactions
2024 · Chandran Nithin, Sebastian Kmiecik, et al. · Nucleic Acids Research · 47
Discovery and Pharmacokinetics of Sulfamides and Guanidines as Potent Human Arginase 1 Inhibitors
2020 · Roman Blaszczyk, Joanna Brzezinska, et al. · ACS Medicinal Chemistry Letters · 46
Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · Molecular Cancer Therapeutics · 44
PDF
OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer
2022 · Marcin Mikołaj Grzybowski, Paulina Seweryna Stańczak, et al. · Cancers · 44
PDF
Novel orally bioavailable piperidine derivatives as extracellular arginase inhibitors developed by a ring expansion
2023 · Anna Gzik, Bartlomiej Borek, et al. · European Journal of Medicinal Chemistry · 13
Therapeutic inhibition of USP7 promotes antitumor immune responses
2025 · Angelika Muchowicz, Katarzyna M Głuchowska, et al. · Journal for ImmunoTherapy of Cancer · 10
PDF
Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy
2017 · P.S. Stanczak, M.M. Grzybowski, et al. · Annals of Oncology · 10
Targeting ARG2 as a novel therapeutic approach for cancer
2019 · M.M. Grzybowski, J. Pęczkowicz-Szyszka, et al. · Annals of Oncology · 6
Structure-Guided Discovery of OAT-4828 as Potent, Selective, and Orally Bioavailable USP7 Inhibitor with In Vivo Antileukemic Activity
2026 · Jacek Chrzanowski, Julita Nowicka, et al. · Journal of Medicinal Chemistry · 2
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · 2
Supplementary Figure 21 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Tables 1-11 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 15 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Materials and Methods from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 23 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 19 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 18 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 20 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figures 2 - 14 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Works count: 69
Citation count: 224
H-index: 7
I10-index: 7
Year
Topic
Type